secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-134303
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Q1 revenue $98.5M (+15.4% YoY); AGAMREE launch adds $1.2M
------------------------------------------------------------------

- Total Q1 2024 net product revenue $98.5M, up 15.4% YoY; FIRDAPSE net revenue $66.8M (+16.2%).
- AGAMREE contributed $1.2M net revenue in first two weeks of U.S. launch, surpassing initial expectations.
- GAAP net income $23.3M ($0.19 diluted EPS); Non-GAAP net income $46.8M ($0.38 diluted EPS).
- Cash and cash equivalents $310.4M as of March 31, 2024, a 125.5% increase from year-end 2023.
- Full-year 2024 total revenue guidance reaffirmed at $455M-$475M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524134303/0001193125-24-134303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524134303/d837068d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer